Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use

A compound of the formula I:

• wherein
• X is a single bond or a straight or branched, saturated or unsaturated chain containing 1 to 6 carbon atoms, wherein one or more of the carbon atoms are optionally independently replaced with O or S, and wherein one or more of the hydrogen atoms are optionally replaced with F;
• Y is a single bond, —CH(OH)—, or —C(O)—;
• R1 is an aryl group, a heteroaryl group, a cycloalkyl group, or a heterocycloalkyl group;
• R2 is H, an alkyl group, an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, or C(O)R10,
• wherein R10 is H, an alkyl group, an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, an O-aryl group, an O-alkyl group, or NR11R12;
• wherein R11 is H, an alkyl group, an O-alkyl group, an aryl group, a heteroaryl group, a cycloalkyl group, or a heterocycloalkyl group, and
• wherein R12 is H, an alkyl group, an aryl group, a heteroaryl group, a cycloalkyl group, or a heterocycloalkyl group,
• or wherein R11 and R12 form, together with the nitrogen to which they are attached, a heteroaryl group or a heterocycloalkyl group, and
• R3 is H, an alkyl group, an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, NR11R12, or OR11 wherein R11 and R12 are as defined above,
• or R2 and R3, together with the atom(s) to which they are attached, form a cycloalkyl group or a heterocycloalkyl group;
• R4 is H or any suitable organic moiety;
• R5 is C(O)NHOH, C(O)OR13, SH, N(OH)CHO, SC(O)R14, P(O)(OH)R15 or P(O)(OH)OR13,
• R13 is H, an alkyl group, or an aryl group,
• R14 is an alkyl group or an aryl group, and
• R15 is an alkyl group;
• and
• is a heteroaryl group having five ring atoms, including 1, 2 or 3 S heteroatoms;
• or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable prodrug thereof, said prodrug being different from a compound of the formula (I).